Elite endurance performance held through allogeneic transplant recovery
An elite endurance runner sustained unusually high aerobic capacity after allogeneic hematopoietic cell transplantation, even as marrow aplasia, donor lymphocyte infusions, chronic graft-versus-host disease, and corticosteroid therapy reshaped the transplant course. The case is striking because the physiologic burden was not abstract: it involved daily training, serial cardiopulmonary exercise testing, and race performances recorded during active immunosuppression.
The patient was 54 years old and had already established an extraordinary athletic profile before transplant. His background included a sub-4-minute mile and a 2:10 marathon, along with ongoing structured workouts that remained fast by any competitive standard. Before transplant, directly measured VO2peak reached 75.8 mL/kg/min, with ventilatory thresholds at approximately 53.0 mL/kg/min for VT1 and 66.0 mL/kg/min for VT2. Those values formed the physiologic baseline against which the transplant period can be read.
Training began while marrow was still aplastic
Structured treadmill exercise resumed on Day +1 after matched-sibling peripheral blood stem cell transplantation for diffuse large B-cell lymphoma transformed from follicular lymphoma. Exercise did not pause for the usual early transplant hazards. He trained through marrow aplasia, then progressed to timed running within 100 days of transplant.
The bedside significance is immediate. Early post-transplant care usually favors caution, with infection prevention, transfusion support, and mobilization that is conservative by design. In this case, the patient’s own training record shows that a highly conditioned athlete can preserve a pattern of structured exertion even while the immune system is rebuilding and hematologic recovery is incomplete. The physiology may partly explain why this was possible: a trained endurance system can operate with a large cardiovascular reserve, allowing submaximal training to remain sustainable even as inflammatory and treatment-related stressors accumulate.
His daily logs were unusually detailed, linking treadmill speed, incline, duration, heart rate, and perceived exertion to transplant milestones and immunosuppression. Resting and exercise heart rate were used to calculate heart rate reserve, and the participant then prescribed subsequent sessions using the peak heart rate from his most recent maximal treadmill test. In other words, training was not improvised; it remained structured, quantifiable, and anchored to objective physiology.
cGvHD and prednisone did not halt performance
The most clinically consequential segment of the case came later, when aerobic performance persisted despite active chronic graft-versus-host disease and treatment with prednisone plus cyclosporine. He recorded a 5K time of 17:55 on Day +314 and a 10K time of 41:00 on Day +340 while on that regimen. Those race results matter because they occurred during a phase when many transplant survivors are still rebuilding basic functional capacity, and corticosteroids can erode muscle function, alter substrate handling, and blunt training adaptation.
The preservation of performance does not mean transplant stress was absent. It means the patient retained enough cardiorespiratory reserve and training continuity to keep competing at a very high level even as immune complications were being managed. For endurance athletes, the early ventilatory threshold often governs pace more than peak oxygen uptake alone. A runner may lose some top-end capacity and still produce fast race times if the metabolic cost of submaximal work stays favorable and the threshold remains high relative to race demand.
Serial exercise testing showed only modest physiologic decline
Post-transplant cardiopulmonary testing documented some reduction, but not the dramatic collapse that might be expected after intensive chemotherapy, transplant conditioning, and corticosteroid exposure. At 7 months after HCT, VO2peak measured 71.5 mL/kg/min, down from 75.8 mL/kg/min before transplant. VT1 fell from 53.0 to 48.0 mL/kg/min, and VT2 from 66.0 to 59.9 mL/kg/min. By 20 months post-HCT, VT1 remained identifiable at 42.4 mL/kg/min, although the test was submaximal and VO2peak could not be determined.
The absolute values are still elite by any standard. What changed was the physiologic margin, not the fundamental athletic phenotype. In practical terms, that means the patient remained capable of sustained aerobic work despite a transplant history that commonly leads to longer-term fitness loss. The fact that the 20-month assessment ended at an RPE of 7.5 and did not reach maximal criteria also reinforces a point often missed in routine survivorship care: serial exercise testing in complex transplant patients can be constrained by clinical judgment, not just physiologic capacity.
Why this case matters for transplant recovery
Allogeneic transplantation places simultaneous stress on hematologic recovery, inflammatory control, and neuromuscular function. Chronic graft-versus-host disease and corticosteroids can further erode exercise tolerance through muscle catabolism, reduced peripheral oxygen utilization, and fatigue. Against that background, maintenance of a VO2peak above 70 mL/kg/min after transplant is exceptional and suggests a substantial interaction between lifelong training status and recovery trajectory.
This case also expands what is usually meant by “exercise during transplant recovery.” The published transplant literature has largely centered on low-intensity ambulation or supervised rehabilitation. Here, performance-oriented endurance training continued across the most vulnerable phases of care, including cytopenia and active cGvHD. The report therefore adds a distinct kind of physiologic evidence: not simply that exercise is feasible after HCT, but that high-level aerobic performance can remain intact in a patient with unusually high baseline fitness and disciplined, continuous training.
The biological plausibility is straightforward enough. Endurance training enlarges stroke volume, improves peripheral oxygen extraction, and shifts ventilatory thresholds to higher workloads. Those adaptations create reserve. When transplant-related stress arrives, the reserve may buffer some of the decline that would otherwise appear in a less trained person. Even so, this is a single case, and the patient’s prior athletic capacity was extraordinary. Generalizing from one elite runner to the broader transplant population would be inappropriate.
A single case, not a template
The main limitation is the nature of the evidence itself. This is one patient, and his baseline physiology was far outside the norm. The CPET assessments were also not fully standardized across time, and the 20-month test was intentionally submaximal, limiting direct comparison with the earlier maximal tests. Some threshold values were estimated retrospectively from graphical output rather than derived from uniform breath-by-breath reanalysis.
Even with those constraints, the longitudinal pattern is hard to ignore. Structured exercise began essentially immediately after transplantation, continued through marrow aplasia, persisted during immunosuppressive treatment for cGvHD, and was accompanied by preserved race performance and only modest reductions in measured aerobic indices. For clinicians following transplant survivors, the case is a reminder that functional recovery can be far more heterogeneous than generic post-transplant guidance assumes, especially when the patient enters treatment with an elite endurance phenotype and remains active throughout the course.